Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals

Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.

Red Blood Cells

Sanofi is in the midst of building out a new blood disorder franchise after completing its acquisition of Bioverativ Inc. in 2018 and launching the rare blood disease treatment Cablivi this year. The business area is expected to be a big growth driver for the company, but it’s also a competitive field that Sanofi will have to navigate.

Sanofi Genzyme exec VP Bill Sibold talked to Scrip in an interview in New York on 14 May about building...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip